<DOC>
	<DOCNO>NCT00445042</DOCNO>
	<brief_summary>The purpose study determine safety toxicity level Dose Escalated Sorafenib treatment patient renal cancer .</brief_summary>
	<brief_title>Safety Toxicity Study Sorafenib Patients With Kidney Cancer</brief_title>
	<detailed_description>Because tumor may multiple mechanism induce angiogenesis , blockade sorafenib may demonstrate efficacy . Doses sorafenib ( 400 mg b.i.d . ) single agent minimal toxicity , present opportunity explore intensive drug administration . This study allow individual patient titration ( e , g , , intrapatient dose escalation ) per protocol . This provide basis dose escalation development sorafenib . The study design evaluate ability patient dose escalate . Secondary endpoint include ; response , time progression , overall survival patient MRCC . Tissue correlation evaluate impact expression receptor clinical outcome retrospectively perform . Laboratory correlation plasma VEGF level correlate evaluated clinical outcome .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytological confirm metastatic unresectable clear cell renal cell carcinoma . No one prior systemic therapy . No prior vascular endothelial growth factor receptor agent . Patients primary tumor place strongly encourage undergo nephrectomy prior initiation study agent . Prior palliative radiotherapy metastatic lesion ( ) permit . All major surgery type and/or radiotherapy must complete least 4 week prior registration . Patients must metastatic unresectable disease . Paraffin RCC tissue block unstained slide must available . Karnofsky performance status &gt; 70 % . Not pregnant Age &gt; 18 Must meet required initial laboratory value No ongoing hemoptysis , cerebrovascular accident within 12 month , peripheral vascular disease claudication le 1 block , history clinically significant bleeding . No deep vein thrombosis pulmonary embolus within one year study enrollment ongoing need fulldose oral parenteral anticoagulation . Low dose coumadin ( 1 mg ) maintenance catheter patency daily prophylactic aspirin allow . No evidence current central nervous system ( CNS ) metastasis . All patient must undergo MRI CT scan brain ( contrast , possible ) within 42 day prior registration . Any imaging abnormality indicative CNS metastasis exclude patient study . No significant cardiovascular disease define congestive heart failure ( New York Heart Association Class II , II IV ) angina pectoris require nitrate therapy , recent myocardial infarction ( within last 6 month ) . No patient uncontrolled hypertension ( define blood pressure &gt; 160 mmHg systolic and/or &gt; 90 mmHg diastolic medication ) . Any ongoing requirement systemic corticosteroid therapy permit . Topical and/or inhale steroid allow . No preexist thyroid abnormality whose thyroid function maintain normal range medication ineligible . No uncontrolled psychiatric disorder . Patients delay heal wound , ulcer and/or bone fracture eligible Patients 'currently active ' second malignancy nonmelanoma skin cancer eligible . Patients consider 'currently active ' malignancy complete anticancer therapy consider physician less 30 % risk relapse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>Metastatic RCC</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>M3thodist</keyword>
</DOC>